Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Rebecca Clark-Snow"'
Publikováno v:
Cancer Medicine, Vol 7, Iss 7, Pp 2943-2950 (2018)
Abstract Most patients receiving highly or moderately emetogenic chemotherapy experience chemotherapy‐induced nausea and vomiting without antiemetic prophylaxis. While neurokinin‐1 receptor antagonists (NK‐1RAs) effectively prevent emesis, thei
Externí odkaz:
https://doaj.org/article/2749e8759f9d4cb8a869026339ebdbea
Autor:
Silvia Olivari, Gary Binder, Erminio Bonizzoni, Eric Roeland, Rudolph M. Navari, Rebecca Clark-Snow
Publikováno v:
Future Oncology. 17:3027-3035
Aim: In the absence of comparative studies, guidelines consider neurokinin 1 receptor antagonists (RAs) as interchangeable. We evaluated the pooled efficacy from three cisplatin registration trials, each with arms containing netupitant/palonosetron (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::895aa406bbd14936f502de265d8b0194
https://doi.org/10.2217/fon-2021-0023
https://doi.org/10.2217/fon-2021-0023
Autor:
William L. Bailey, Kathryn J. Ruddy, Lee S. Schwartzberg, Rebecca Clark-Snow, Thomas W. LeBlanc, Eric Roeland, Rudolph M. Navari, Luke M. Schmerold, Ryan D. Nipp, Ravi Potluri, Eros Papademetriou, Gary Binder
Publikováno v:
Oncologist
Purpose Chemotherapy-induced nausea and vomiting (CINV) contributes to avoidable acute care, a metric now tracked in Medicare's oncology outcome measure. CINV is preventable, yet guidelines are often not followed. We sought to quantify acute care inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65f82d33fd3c5e74917a8e460cb39dd1
https://doi.org/10.1002/onco.13620
https://doi.org/10.1002/onco.13620
Autor:
Kristopher Dennis, Kimberly Noonan, Paul J. Hesketh, Dee Sparacio, Sally Y. Barbour, Stacie B. Dusetzina, Rebecca Clark-Snow, Kari Bohlke, Petra Feyer, Karin Jordan, Cathy Eng, Gary H. Lyman, L. Lee Dupuis, Ethan Basch, Michael A. Danso, Mark G. Kris
Publikováno v:
Journal of Clinical Oncology. 38:2782-2797
PURPOSE To update the guideline to include new anticancer agents, antiemetics, and antiemetic regimens and to provide recommendations on the use of dexamethasone as a prophylactic antiemetic in patients receiving checkpoint inhibitors (CPIs). METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b91b52a922e96749ce01e6cce47261a
https://doi.org/10.1200/jco.20.01296
https://doi.org/10.1200/jco.20.01296
Autor:
Gary Binder, Lee S. Schwartzberg, Rita Wickham, Ravi Potluri, Thomas W. LeBlanc, William L. Bailey, Kathryn J. Ruddy, Rudolph M. Navari, Eric Roeland, Rebecca Clark-Snow, Luke M. Schmerold, Eros Papademetriou
Publikováno v:
Cancer Research. 80:P5-14
Background: Anthracycline and cyclophosphamide (AC) is a highly emetogenic chemotherapy (HEC) regimen. Combination netupitant/palonosetron (NEPA) + dexamethasone (DEX) is guideline-recommended for prophylaxis of chemotherapy-induced nausea and vomiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e0ddd3a8b76dd5dd41213ac4bdb2b4a
https://doi.org/10.1158/1538-7445.sabcs19-p5-14-07
https://doi.org/10.1158/1538-7445.sabcs19-p5-14-07
Autor:
Giada Rizzi, Lee S. Schwartzberg, Rebecca Clark-Snow, Ekaterine Arkania, Richard J. Gralla, Rudolph M. Navari, Matti Aapro, Daniel Voisin, Rita Wickham, Irena Radyukova, Kamal Patel, Eric Roeland
Publikováno v:
The Oncologist
Background NEPA, a combination antiemetic of a neurokinin‐1 (NK1) receptor antagonist (RA) (netupitant [oral]/fosnetupitant [intravenous; IV]) and 5‐HT3RA, palonosetron] offers 5‐day CINV prevention with a single dose. Fosnetupitant solution co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68c86b440d6ed206d816898d33b60fe1
https://doi.org/10.1634/theoncologist.2019-0527
https://doi.org/10.1634/theoncologist.2019-0527
Publikováno v:
Supportive Care in Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9367bffec349032a855dbcf7596dfdd0
Publikováno v:
Cancer Medicine, Vol 7, Iss 7, Pp 2943-2950 (2018)
Cancer Medicine
Cancer Medicine
Most patients receiving highly or moderately emetogenic chemotherapy experience chemotherapy‐induced nausea and vomiting without antiemetic prophylaxis. While neurokinin‐1 receptor antagonists (NK‐1RAs) effectively prevent emesis, their ability
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84f37ebbccc4e9ad719b05c03df04600
https://doi.org/10.1002/cam4.1560
https://doi.org/10.1002/cam4.1560
Autor:
Kathryn J. Ruddy, Ravi Potluri, Rebecca Clark-Snow, Rita J Wickham, Thomas W. LeBlanc, Gary Binder, Rudolph M. Navari, Luke M. Schmerold, Tammy Bratton Coberly, Eric Roeland
Publikováno v:
JCO oncology practice. 16(2)
PURPOSE: After ASCO and National Comprehensive Cancer Network guideline recommendations for triple antiemetic prophylaxis for carboplatin area under the curve (AUC) ≥ 4, and the publication of studies documenting avoidable acute care after chemothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f84d11d0c535f67ef2888a3ee438d78e
https://pubmed.ncbi.nlm.nih.gov/31800352
https://pubmed.ncbi.nlm.nih.gov/31800352
Autor:
Rudolph M. Navari, Luke M. Schmerold, Eros Papademetriou, Ravi Potluri, Silvia Sebastiani, Gary Binder, Rebecca Clark-Snow, Rita Wickham, Kathryn Ruddy, Eric Roeland
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3987da2969c1a18ca37eda2be263b1c
https://doi.org/10.26226/morressier.5cdbe0a3618793e647b11ce6
https://doi.org/10.26226/morressier.5cdbe0a3618793e647b11ce6
